Kiovig (Human Normal Immunoglobulin)

Human normal immunoglobulin, the active ingredient in Kiovig, is an immunoglobulin presented as an injectable solution for intravenous use. It treats primary and secondary immunodeficiency diseases, Kawasaki disease, immune thrombocytopenic purpura, and chronic inflammatory demyelinating polyneuropathy in appropriate patients.

GNH USA supplies Kiovig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Kiovig is used in immunoglobulin replacement therapy to address deficiencies or dysregulation of the immune system. - Primary immunodeficiency diseases: restores IgG levels to reduce infection frequency. - Secondary immunodeficiency (e.g., chemotherapy, HIV): provides passive immunity to protect against opportunistic infections. - Kawasaki disease: reduces inflammation and fever in the acute phase. - Immune thrombocytopenic purpura (ITP): helps raise platelet counts by modulating auto‑immune activity. - Chronic inflammatory demyelinating polyneuropathy (CIDP): improves muscle strength and functional ability by dampening autoimmune nerve damage.

Adverse reactions to Kiovig may range from mild infusion‑related events to rare but serious systemic effects.

Common Side Effects: - Headache: mild to moderate pain during or after infusion. - Fever or chills: transient temperature rise. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: blood clots such as deep vein thrombosis. - Renal impairment: acute kidney injury, especially with rapid infusion.

Before using Kiovig, clinicians should consider several precautionary measures to ensure patient safety. - Assess IgG levels: confirm deficiency or indication before initiation. - Screen for IgA deficiency: patients with anti‑IgA antibodies may be at risk of severe reactions. - Monitor infusion rate: start slowly and adjust to reduce adverse events. - Evaluate renal function: adjust therapy in patients with pre‑existing kidney disease. - Review thrombotic risk: consider history of clotting disorders before high‑dose infusions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kiovig can interact with certain medications or clinical conditions, influencing safety or efficacy.

Major Interactions (Avoid): - Live vaccines: concurrent use may reduce vaccine efficacy and increase infection risk. - High‑dose aspirin or NSAIDs: may increase bleeding tendency during infusion.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclophosphamide): may alter infection risk profile. - Diuretics: can affect fluid balance during large‑volume infusions. - Anticoagulants (e.g., warfarin): monitor coagulation parameters as infusion may affect plasma volume.